Effect of Y-90 SIR-Spheres Therapy for Multiple Liver Metastases in a Variety of Tumors
- *Corresponding Author:
- Dr. Isis W. Gayed, M.D.,
University of Texas-Houston,
Medical School, Department of Radiology, 6431 Fannin, Suite 2.130b,
Houston, Texas 77030,
E-mail: Isis.W.Gayed @uth.tmc.edu
Received Date: February 22, 2010; Accepted Date: March 29, 2010; Published Date: March 29, 2010
Citation: Gayed IW, Wahba H, Wan D, Joseph U, Murthy R (2010) Effect of Y-90 SIR-Spheres Therapy for Multiple Liver Metastases in a Variety of Tumors. J Cancer Sci Ther 2: 043-046. doi: 10.4172/1948-5956.1000021
Copyright: © 2010 Gayed IW, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective To evaluate the outcomes of patients receiving Y- 90 SIR-Spheres in patients with multiple liver metastases from different tumors. Methods: 29 consecutive patients with multiple liver metastases from colorectal (13), Islet cell tumors (9), carcinoid tumors (4) or non-small cell lung cancer (3) who were treated with Y-90 SIR-Spheres between March, 2003 and February, 2006 were included. Only patients who had follow-up radiological exams at our institution were included. Data regarding Y-90 SIR-Spheres dose, lobe of liver treated, and chemotherapy (CTx) administered were collected. Patients’ outcomes were evaluated based on radiological evidence of change in size and number of liver metastases. Results: The study population included 8 females and 21 males at a mean age of 60y. The mean Y-90 SIR-Spheres dose administered was 39.8 mCi. Both lobes of the liver, the right lobe only or the left lobe only were treated in 26, 2, 1 patients, respectively. Sixteen patients received Y-90 SIR-Spheres after CTx failure, 5 patients as adjuvant therapy after completion of CTx, 7 patients as concurrent therapy and one patient refused repeat CTx. The mean interval between the last CTx and Y-90 SIR-Spheres was 108 days. Four patients (14%) demonstrated radiological improvement and 9 (31%) were stable for a mean interval of 2.8 mo. after Y-90 SIR-Spheres infusion. Sixteen patients (55%) demonstrated continued progress of liver metastases. Conclusion: Y-90 SIR-Spheres therapy is useful in reducing or stabilizing multiple liver metastases from a variety of tumors.